WAT

Waters Corporation (WAT) | Rumor.io

Waters

WAT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,554

Bullish sentiment (50-day avg)100%

Price to earnings ratio110.4

Market capitalization43.5B

Earnings per share3.95

Dividend yield (TTM)—

Revenue (annual)3.2B

Net income (annual)642.6M

Social

What share of all stock conversation is about WAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Feb 9

Waters Corporation reported Q4 2025 sales of $932M, a 7% increase from the previous year, with diluted EPS slightly down to $3.77.
The company's FY 2025 sales were $3,165M, a 7% YoY increase, with non-GAAP EPS of $13.13, an 11% YoY increase.
Waters expects full-year 2026 total revenue of $6.41B to $6.46B, including acquired business contribution, and non-GAAP EPS of $14.30 to $14.50, representing 8.9% to 10.4% growth.

Generated by AI

Sentiment

Of the messages about WAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	72.49% -20.62
Bearish	—	—	0% 0	27.51% +20.62

Jan 24

Waters Corporation ($WAT) has broken out to new all-time highs, a strong technical indicator.
BTIG Research has raised its price target for Waters Corporation ($WAT) to $260.00, citing a buy rating.
Waters Corporation ($WAT) has seen a significant surge in volume, a new 52-week high, and a new uptrend, indicating strong market momentum.

Generated by AI

Topics

Of the messages about WAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	4.26%
Analysts	—	—	—	31.46%
Earnings	—	—	—	1.69%
Controversies	—	—	—	0.01%
Macro	—	—	—	33.09%
Technical Analysis	—	—	—	29.48%

Earnings· May 5

Waters Corporation reported Q1 earnings of $2.29 EPS, beating the estimate of $1.57 EPS by $0.72.
Waters Corporation guided Q2 EPS above consensus and revenue in-line with consensus.
Waters Corporation updated FY21 guidance to $9.85-10.05 EPS and revenue guidance to $2.58-2.67 billion.

Announcements· Jul 14

Waters Corporation ($WAT) is merging with Becton, Dickinson and Company's ($BDX) Biosciences and Diagnostics Solutions business in a $17.5B Reverse Morris Trust deal.
The combined entity will create a life sciences and diagnostics leader with approximately $6.5B in pro forma 2025 revenue and aims to reach $9B in revenue by 2030 with a 32% operating margin.
Waters shareholders will retain 60.8% of the new company, while BD shareholders will receive 39.2% and $4B in cash, with plans to use at least half for share repurchases.

Generated by AI

Community

Of the messages about WAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	21.7%
Newcomers	100%	100%	100%	78.3%

Regulars· Nov 4

Waters reported a Q3 earnings beat with adj. EPS of $3.40, a 16.0% YoY increase, and revenue of $799.9M, an 8.1% YoY increase.
Waters increased its FY25 EPS view to $13.05-$13.15 and its FY25 revenue view to 6.5%-7.1%, both above consensus.
Waters reported Q4 EPS guidance of $4.45-$4.55, below consensus, and Q4 revenue growth of 5%-7%, with margin pressure and weaker cash flow.

Newcomers· Aug 4

Waters Corporation reports Q2 EPS of $2.95, beating the FactSet Consensus of $2.94, and sees EPS of $3.15-3.25 in Q3, with revenue up 8.8% year/year to $771.3 mln.
Waters Corporation raises full-year sales and EPS guidance after Q2 earnings beat, with revenue up 9% year/year and non-GAAP EPS guidance increased to $12.95-$13.05.
Waters Corporation's Q2 revenue beats estimates, with $771.33M in revenue vs. $749.51M consensus, and sees Q3 EPS of $3.15-$3.25, with revenue up 5%-7%.

Generated by AI

In mid-September 2026, Everlywell announced a partnership with Waters Corporation to support at-home HPV cervical cancer screening, while Waters also launched the BD FACSDiscover A7 Cell Analyzer globally, expanding access to advanced flow cytometry for research labs. Together, these moves highlight Waters’ growing role in connected diagnostics and high-parameter cell analysis, deepening its presence across clinical and research workflows. Next, we’ll examine how the expanded at-home HPV...

2d agoYahoo! Finance Canada

Waters Corporation stock hits all-time high at 433.09 USD

5d agoInvesting.com

Waters: Positive Momentum Rides High Again (NYSE:WAT)

6d agoSeeking Alpha

Robust Results Lifted Waters (WAT)

Madison Investments, an investment advisor, released its second-quarter 2026 investor letter for the “Madison Mid Cap Fund”. You can download a copy of the letter here. U.S. stock market indices posted their strongest second-quarter performance since 2020, driven largely by enthusiasm for Artificial Intelligence. Nine of the ten largest companies in the Russell Midcap Index […]

6d agoYahoo Finance

Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry

WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.

11d agoYahoo Finance

How Is Waters Corporation's Stock Performance Compared to Other Health Care Stocks?

11d agoBarchart.com

Also Discussed

Investors talking about WAT also mention

#	Name	Attention
1	Pentair plcPNR	0%0
2	Mettler-Toledo International Inc.MTD	0%new
3	Danaher Corp.DHR	0.02%+0.02
4	IDEXX Laboratories, Inc.IDXX	0%0
5	Brown-Forman Corp. Class B Common StockBF.B	0%0
6	Roper Technologies Inc.ROP	0%+0
7	Becton, Dickinson and CompanyBDX	0%0
8	PKI - PerkinElmer, Inc.	——
9	Edwards Lifesciences CorporationEW	0%new
10	Thermo Fisher Scientific Inc.TMO	0%0

Waters Corporation

Healthcare
Diagnostics & Research

Waters Corporation is a scientific instrumentation company that provides analytical workflow solutions to customers in the life sciences, industrial, and academic sectors. The company specializes in liquid chromatography systems, mass spectrometry platforms, and related precision chemistry consumables that support complex chemical and biochemical analysis. Through its Waters segment, it delivers integrated instruments, software, and services used in drug development, quality control, food and environmental testing, and advanced materials research. Its TA Instruments segment focuses on thermal analysis and rheology equipment that measure material properties such as stability, viscosity, and mechanical performance for industrial and research applications. Waters Corporation serves biopharmaceutical companies, industrial manufacturers, and government and academic laboratories globally, with a particularly strong presence in diagnostics and research-related workflows. Founded in 1958 and headquartered in Milford, Massachusetts, Waters Corporation plays a significant role in enabling precise measurement, regulatory compliance support, and data-driven decision-making across regulated and research-intensive markets.

Website

Location

34 Maple Street

Milford, MA, 01757

United States

Social

What share of all stock conversation is about WAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Feb 9

Waters Corporation reported Q4 2025 sales of $932M, a 7% increase from the previous year, with diluted EPS slightly down to $3.77.
The company's FY 2025 sales were $3,165M, a 7% YoY increase, with non-GAAP EPS of $13.13, an 11% YoY increase.
Waters expects full-year 2026 total revenue of $6.41B to $6.46B, including acquired business contribution, and non-GAAP EPS of $14.30 to $14.50, representing 8.9% to 10.4% growth.

Generated by AI

Sentiment

Of the messages about WAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	72.49% -20.62
Bearish	—	—	0% 0	27.51% +20.62

Jan 24

Waters Corporation ($WAT) has broken out to new all-time highs, a strong technical indicator.
BTIG Research has raised its price target for Waters Corporation ($WAT) to $260.00, citing a buy rating.
Waters Corporation ($WAT) has seen a significant surge in volume, a new 52-week high, and a new uptrend, indicating strong market momentum.

Generated by AI

Topics

Of the messages about WAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	4.26%
Analysts	—	—	—	31.46%
Earnings	—	—	—	1.69%
Controversies	—	—	—	0.01%
Macro	—	—	—	33.09%
Technical Analysis	—	—	—	29.48%

Earnings· May 5

Waters Corporation reported Q1 earnings of $2.29 EPS, beating the estimate of $1.57 EPS by $0.72.
Waters Corporation guided Q2 EPS above consensus and revenue in-line with consensus.
Waters Corporation updated FY21 guidance to $9.85-10.05 EPS and revenue guidance to $2.58-2.67 billion.

Announcements· Jul 14

Waters Corporation ($WAT) is merging with Becton, Dickinson and Company's ($BDX) Biosciences and Diagnostics Solutions business in a $17.5B Reverse Morris Trust deal.
The combined entity will create a life sciences and diagnostics leader with approximately $6.5B in pro forma 2025 revenue and aims to reach $9B in revenue by 2030 with a 32% operating margin.
Waters shareholders will retain 60.8% of the new company, while BD shareholders will receive 39.2% and $4B in cash, with plans to use at least half for share repurchases.

Generated by AI

Community

Of the messages about WAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	21.7%
Newcomers	100%	100%	100%	78.3%

Regulars· Nov 4

Waters reported a Q3 earnings beat with adj. EPS of $3.40, a 16.0% YoY increase, and revenue of $799.9M, an 8.1% YoY increase.
Waters increased its FY25 EPS view to $13.05-$13.15 and its FY25 revenue view to 6.5%-7.1%, both above consensus.
Waters reported Q4 EPS guidance of $4.45-$4.55, below consensus, and Q4 revenue growth of 5%-7%, with margin pressure and weaker cash flow.

Newcomers· Aug 4

Waters Corporation reports Q2 EPS of $2.95, beating the FactSet Consensus of $2.94, and sees EPS of $3.15-3.25 in Q3, with revenue up 8.8% year/year to $771.3 mln.
Waters Corporation raises full-year sales and EPS guidance after Q2 earnings beat, with revenue up 9% year/year and non-GAAP EPS guidance increased to $12.95-$13.05.
Waters Corporation's Q2 revenue beats estimates, with $771.33M in revenue vs. $749.51M consensus, and sees Q3 EPS of $3.15-$3.25, with revenue up 5%-7%.

Generated by AI

Waters

Social

Feb 9

Sentiment

Jan 24

Topics

Earnings· May 5

Announcements· Jul 14

Community

Regulars· Nov 4

Newcomers· Aug 4

News

The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push

Waters Corporation stock hits all-time high at 433.09 USD

Waters: Positive Momentum Rides High Again (NYSE:WAT)

Robust Results Lifted Waters (WAT)

Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry

How Is Waters Corporation's Stock Performance Compared to Other Health Care Stocks?

Also Discussed

Waters Corporation

Company Information

Location

News

The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push

Waters Corporation stock hits all-time high at 433.09 USD

Waters: Positive Momentum Rides High Again (NYSE:WAT)

Robust Results Lifted Waters (WAT)

Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry

How Is Waters Corporation's Stock Performance Compared to Other Health Care Stocks?

Also Discussed

Social

Feb 9

Sentiment

Jan 24

Topics

Earnings· May 5

Announcements· Jul 14

Community

Regulars· Nov 4

Newcomers· Aug 4